Atrayee B. Mallick
Expertise in
40
conditions

Dr. Atrayee B. Mallick

Hematology Oncology | Oncology
1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
40
conditions
1101 Chestnut Street, Floor 14, 
Philadelphia, PA 

Overview

Atrayee Mallick is a Hematologist Oncology specialist and an Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Mallick is highly rated in 40 conditions, according to our data. Her clinical expertise encompasses Bone Tumor, Colorectal Cancer, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Pancreaticoduodenectomy.

Dr. Mallick is board certified in Hematology and Medical Oncology. She is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 3 clinical trials. Dr. Mallick is currently accepting new patients.

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in PA

Board Certifications

Hematology
Medical Oncology

Fellowships

Montefiore Medical Center

Hospital Affiliations

Jefferson Cherry Hill Hospital
Jefferson Methodist Hospital
Jefferson Stratford Hospital
Jefferson Washington Township Hospital
Thomas Jefferson University Hospital
Jefferson Stratford Hospital
Thomas Jefferson University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, Philadelphia, PA 19107

Additional Areas of Focus

Dr. Mallick has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Aplastic Anemia
Cervical Cancer
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Procedure, Genetic
Study Drugs: Bendamustine, Ofatumumab, Carboplatin, Etoposide
Study Phase: Phase 1/Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

20 Total Publications

Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.
Journal: JCO precision oncology
Published: July 02, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Margaret T. Kasner
Hematology Oncology | Palliative Medicine | Oncology
Expertise in
18
conditions
Dr. Margaret T. Kasner
Hematology Oncology | Palliative Medicine | Oncology
Referral may be required
Before you request

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
 (0.1 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Margaret Kasner is a Hematologist Oncology specialist and a Palliative Medicine provider practicing medicine in Philadelphia, Pennsylvania. Dr. Kasner is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kasner is board certified in Hematology and Medical Oncology. Dr. Kasner is currently accepting new patients.

Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Referral may be required
230 W Washington Sq, 2nd Floor, 
Philadelphia, PA 
 (0.4 miles away)
215-829-6088
Languages Spoken:
English
See accepted insurances

Arthur Staddon is a Hematologist Oncology provider practicing medicine in Philadelphia, Pennsylvania. Dr. Staddon is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, and Bone Tumor.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (1.9 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Atrayee B. Mallick

How do I make an appointment with Dr. Atrayee B. Mallick?

You can book an appointment with Dr. Atrayee B. Mallick by calling their office at 215-955-8874. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Atrayee B. Mallick a top-rated expert for Bone Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Atrayee B. Mallick is classified as an Distinguished expert for Bone Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Atrayee B. Mallick specialize in?

While Dr. Atrayee B. Mallick is a Hematology Oncology, they have specific expertise in Bone Tumor, Colorectal Cancer, and Undifferentiated Pleomorphic Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Atrayee B. Mallick participate in research or clinical trials?

Yes. Dr. Atrayee B. Mallick has published 20 articles and abstracts on conditions like Bone Tumor. You can view a list of Dr. Atrayee B. Mallick's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Atrayee B. Mallick accept my insurance?

Dr. Atrayee B. Mallick accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-955-8874 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mallick's expertise for a condition
ConditionClose
    View All 23 Distinguished Conditions
    View All 17 Advanced Conditions
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile